Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
ZYUS Life Sciences ( (TSE:ZYUS) ) has issued an update.
ZYUS Life Sciences has announced the activation of the first clinical site and the enrollment of the first patient in its Phase 2a UTOPIA-1 clinical trial, which aims to evaluate the safety and preliminary analgesic efficacy of Trichomylin® softgel capsules for cancer pain management. This milestone signifies a significant advancement in ZYUS’ clinical development program, highlighting the company’s commitment to providing a novel, non-opioid pain management solution that could improve patient outcomes and offer long-term value for shareholders.
The most recent analyst rating on (TSE:ZYUS) stock is a Buy with a C$1.50 price target. To see the full list of analyst forecasts on ZYUS Life Sciences stock, see the TSE:ZYUS Stock Forecast page.
More about ZYUS Life Sciences
ZYUS Life Sciences Corporation is a clinical-stage life sciences company focused on the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates for pain management. The company aims to secure intellectual property protection and obtain regulatory approval for non-opioid-based pharmaceutical solutions, with a focus on transforming patient lives and enhancing shareholder value.
Average Trading Volume: 12,621
Technical Sentiment Signal: Sell
Current Market Cap: C$47.25M
See more data about ZYUS stock on TipRanks’ Stock Analysis page.